Resource impact statement
No significant resource impact is anticipated
NICE has recommended secukinumab as an option for treating plaque psoriasis in children and young people aged 6 to 17 years, only if:
- the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
- the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated.
Please see the guidance for further details.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option which is available at a similar price to current treatment options and the eligible population is small. Around 180 children and young people are expected to be eligible for treatment.
Secukinumab has a discount that is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: